A. Shai

发表

Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas.

Susan M. Chang, Marram P. Olson, M. Berger, 2019, Neuro-oncology.

Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.

Jennie W. Taylor, Jacob S. Young, Susan M. Chang, 2020, JAMA oncology.

Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1

Jennie W. Taylor, Michael A. Rodriguez, Susan M. Chang, 2022, Acta Neuropathologica.

A role for HPV16 E5 in cervical carcinogenesis.

H. Pitot, P. Lambert, John P. Maufort, 2010, Cancer research.

A Role for HPV 16 E 5 in Cervical Carcinogenesis

H. Pitot, P. Lambert, John P. Maufort, 2010 .

Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.

Susan M. Chang, Marram P. Olson, V. Pedoia, 2021, Neuro-oncology.

MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.

H. Zhang, T. Golub, D. Hanahan, 2009, Genes & development.

TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.

M. McMahon, D. Dankort, A. Shai, 2015, Cancer research.

p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers.

H. Pitot, P. Lambert, A. Shai, 2008, Cancer research.

Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas

Jennie W. Taylor, Susan M. Chang, P. Theodosopoulos, 2021, The Journal of clinical investigation.

Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.

Jennie W. Taylor, Susan M. Chang, M. Berger, 2021, Neuro-oncology.

Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis.

P. Lambert, M. Tommasino, L. Sherman, 2009, Virology.

The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities.

P. Lambert, C. Somoza, A. Shai, 2007, Cancer research.

Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer.

K. Korach, P. Lambert, A. Shai, 2008, Cancer research.

Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma

M. Berger, K. Auguste, K. Wendelsdorf, 2019, Acta Neuropathologica.

HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background

L. Banks, P. Lambert, P. Massimi, 2008, Oncogene.

Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma

Jennie W. Taylor, Jacob S. Young, Susan M. Chang, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP

P. Lambert, J. Wagstaff, Y. Jiang, 2007, Oncogene.

Tumor and Stem Cell Biology Cancer Research E 6-Associated Protein Is Required for Human Papillomavirus Type 16 E 6 to Cause Cervical Cancer in Mice

H. Pitot, P. Lambert, A. Shai, 2010 .